Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Melatonin-Aluminum Oxide-Polymethylsiloxane Complex on Apoptosis of Liver Cells in a Model of Obesity and Type 2 Diabetes Mellitus.

Michurina SV, Ischenko IY, Arkhipov SA, Klimontov VV, Cherepanova MA, Korolev MA, Rachkovskaya LN, Zav'yalov EL, Konenkov VI.

Bull Exp Biol Med. 2017 Dec;164(2):165-169. doi: 10.1007/s10517-017-3949-x. Epub 2017 Nov 27.

PMID:
29181668
2.

KRAS-dependent suppression of MYC enhances the sensitivity of cancer cells to cytotoxic agents.

Ischenko I, Zhi J, Hayman MJ, Petrenko O.

Oncotarget. 2017 Mar 14;8(11):17995-18009. doi: 10.18632/oncotarget.14929.

3.

Effect of Linagliptin on Structural Changes in the Kidney in Experimental Type 2 Diabetes Mellitus.

Gavrilova YS, Bgatova NP, Klimontov VV, Ischenko IY, Michurina SV, Myakina NE, Zavyalov EL.

Bull Exp Biol Med. 2016 Aug;161(4):501-4. doi: 10.1007/s10517-016-3447-6. Epub 2016 Sep 3.

PMID:
27591880
4.

[Liver and Its Lymph Region at Benzo[a]pyrene Effects in an Experiment].

Michurina SV, Borodin IuI, Kolesnikov SI, Ischenko IIu, Konenkov VI.

Vestn Ross Akad Med Nauk. 2015;(2):242-8. Russian.

PMID:
26234098
5.

On involvement of transcription factors nuclear factor kappa-light-chain-enhancer of activated B cells, activator protein-1 and signal transducer and activator of transcription-3 in photodynamic therapy-induced death of crayfish neurons and satellite glial cells.

Berezhnaya E, Neginskaya M, Kovaleva V, Sharifulina S, Ischenko I, Komandirov M, Rudkovskii M, Uzdensky AB.

J Biomed Opt. 2015 Jul;20(7):75004. doi: 10.1117/1.JBO.20.7.075004.

PMID:
26160345
6.

A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells.

Ischenko I, Petrenko O, Hayman MJ.

Oncotarget. 2015 Jun 30;6(18):15814-27.

7.

Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer.

Zhao Y, Zhao L, Ischenko I, Bao Q, Schwarz B, Nieß H, Wang Y, Renner A, Mysliwietz J, Jauch KW, Nelson PJ, Ellwart JW, Bruns CJ, Camaj P.

Target Oncol. 2015 Dec;10(4):535-48. doi: 10.1007/s11523-015-0360-2. Epub 2015 Feb 3.

PMID:
25639539
8.

Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.

Niess H, Camaj P, Renner A, Ischenko I, Zhao Y, Krebs S, Mysliwietz J, Jäckel C, Nelson PJ, Blum H, Jauch KW, Ellwart JW, Bruns CJ.

Target Oncol. 2015 Jun;10(2):215-27. doi: 10.1007/s11523-014-0323-z. Epub 2014 Jun 22.

PMID:
24950733
9.

Transforming growth factor-beta signaling network regulates plasticity and lineage commitment of lung cancer cells.

Ischenko I, Liu J, Petrenko O, Hayman MJ.

Cell Death Differ. 2014 Aug;21(8):1218-28. doi: 10.1038/cdd.2014.38. Epub 2014 Mar 28.

10.

Analysis of the tumor-initiating and metastatic capacity of PDX1-positive cells from the adult pancreas.

Ischenko I, Petrenko O, Hayman MJ.

Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3466-71. doi: 10.1073/pnas.1319911111. Epub 2014 Feb 18.

11.

Ron tyrosine kinase receptor synergises with EGFR to confer adverse features in head and neck squamous cell carcinoma.

Keller J, Nimnual AS, Shroyer KR, Joy C, Ischenko I, Chandler CS, Dong LM, Hayman MJ, Chan EL.

Br J Cancer. 2013 Jul 23;109(2):482-92. doi: 10.1038/bjc.2013.321. Epub 2013 Jun 25.

12.

Direct reprogramming by oncogenic Ras and Myc.

Ischenko I, Zhi J, Moll UM, Nemajerova A, Petrenko O.

Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3937-42. doi: 10.1073/pnas.1219592110. Epub 2013 Feb 19.

13.

Cancer stem cells and angiogenesis.

Zhao Y, Bao Q, Renner A, Camaj P, Eichhorn M, Ischenko I, Angele M, Kleespies A, Jauch KW, Bruns C.

Int J Dev Biol. 2011;55(4-5):477-82. doi: 10.1387/ijdb.103225yz. Review.

14.

Risk factors for surgical complications in distal pancreatectomy.

Seeliger H, Christians S, Angele MK, Kleespies A, Eichhorn ME, Ischenko I, Boeck S, Heinemann V, Jauch KW, Bruns CJ.

Am J Surg. 2010 Sep;200(3):311-7. doi: 10.1016/j.amjsurg.2009.10.022. Epub 2010 Apr 9.

PMID:
20381788
15.

Src tyrosine kinase inhibition suppresses lymphangiogenesis in vitro and in vivo.

Ischenko I, Seeliger H, Camaj P, Kleespies A, Guba M, Eichhorn ME, Jauch KW, Bruns CJ.

Curr Cancer Drug Targets. 2010 Aug;10(5):546-53.

PMID:
20370688
16.

The marine compound spongistatin 1 targets pancreatic tumor progression and metastasis.

Rothmeier AS, Schneiders UM, Wiedmann RM, Ischenko I, Bruns CJ, Rudy A, Zahler S, Vollmar AM.

Int J Cancer. 2010 Sep 1;127(5):1096-105. doi: 10.1002/ijc.25241.

17.

Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma.

Zischek C, Niess H, Ischenko I, Conrad C, Huss R, Jauch KW, Nelson PJ, Bruns C.

Ann Surg. 2009 Nov;250(5):747-53. doi: 10.1097/SLA.0b013e3181bd62d0. Erratum in: Ann Surg. 2010 Jan;251(1):187.

PMID:
19826249
18.

EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells.

Camaj P, Seeliger H, Ischenko I, Krebs S, Blum H, De Toni EN, Faktorova D, Jauch KW, Bruns CJ.

Biol Chem. 2009 Dec;390(12):1293-302. doi: 10.1515/BC.2009.140.

PMID:
19804359
19.

Metastatic activity and chemotherapy resistance in human pancreatic cancer--influence of cancer stem cells.

Ischenko I, Seeliger H, Jauch KW, Bruns CJ.

Surgery. 2009 Sep;146(3):430-4. doi: 10.1016/j.surg.2009.05.003. Epub 2009 Jun 25. Review. No abstract available.

PMID:
19715799
20.

Vascular targeting by EndoTAG-1 enhances therapeutic efficacy of conventional chemotherapy in lung and pancreatic cancer.

Eichhorn ME, Ischenko I, Luedemann S, Strieth S, Papyan A, Werner A, Bohnenkamp H, Guenzi E, Preissler G, Michaelis U, Jauch KW, Bruns CJ, Dellian M.

Int J Cancer. 2010 Mar 1;126(5):1235-45. doi: 10.1002/ijc.24846.

21.

Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications.

Ischenko I, Seeliger H, Kleespies A, Angele MK, Eichhorn ME, Jauch KW, Bruns CJ.

Langenbecks Arch Surg. 2010 Jan;395(1):1-10. doi: 10.1007/s00423-009-0502-z. Epub 2009 May 7. Review.

PMID:
19421768
22.

EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma.

Seeliger H, Camaj P, Ischenko I, Kleespies A, De Toni EN, Thieme SE, Blum H, Assmann G, Jauch KW, Bruns CJ.

Mol Cancer Res. 2009 Feb;7(2):189-98. doi: 10.1158/1541-7786.MCR-08-0132. Epub 2009 Feb 10.

23.

Cancer stem cells: how can we target them?

Ischenko I, Seeliger H, Schaffer M, Jauch KW, Bruns CJ.

Curr Med Chem. 2008;15(30):3171-84. Review.

PMID:
19075661
24.

Investigation of the marine compound spongistatin 1 links the inhibition of PKCalpha translocation to nonmitotic effects of tubulin antagonism in angiogenesis.

Rothmeier AS, Ischenko I, Joore J, Garczarczyk D, Fürst R, Bruns CJ, Vollmar AM, Zahler S.

FASEB J. 2009 Apr;23(4):1127-37. doi: 10.1096/fj.08-117127. Epub 2008 Dec 4.

PMID:
19056838
25.

The RON receptor tyrosine kinase promotes MSP-independent cell spreading and survival in breast epithelial cells.

Feres KJ, Ischenko I, Hayman MJ.

Oncogene. 2009 Jan 15;28(2):279-88. doi: 10.1038/onc.2008.383. Epub 2008 Oct 6.

26.

Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling.

Ischenko I, Camaj P, Seeliger H, Kleespies A, Guba M, De Toni EN, Schwarz B, Graeb C, Eichhorn ME, Jauch KW, Bruns CJ.

Oncogene. 2008 Dec 4;27(57):7212-22. doi: 10.1038/onc.2008.326. Epub 2008 Sep 15.

PMID:
18794807
27.

Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine.

Kleespies A, Ischenko I, Eichhorn ME, Seeliger H, Amendt C, Mantell O, Jauch KW, Bruns CJ.

Clin Cancer Res. 2008 Sep 1;14(17):5426-36. doi: 10.1158/1078-0432.CCR-07-5245.

28.

Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer.

Ischenko I, Guba M, Yezhelyev M, Papyan A, Schmid G, Green T, Fennell M, Jauch KW, Bruns CJ.

Angiogenesis. 2007;10(3):167-82. Epub 2007 May 8.

PMID:
17486419
29.

Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.

Conrad C, Ischenko I, Köhl G, Wiegand U, Guba M, Yezhelyev M, Ryan AJ, Barge A, Geissler EK, Wedge SR, Jauch KW, Bruns CJ.

Anticancer Drugs. 2007 Jun;18(5):569-79.

PMID:
17414626
30.

Nitric oxide inhibits enterocyte migration through activation of RhoA-GTPase in a SHP-2-dependent manner.

Cetin S, Leaphart CL, Li J, Ischenko I, Hayman M, Upperman J, Zamora R, Watkins S, Ford HR, Wang J, Hackam DJ.

Am J Physiol Gastrointest Liver Physiol. 2007 May;292(5):G1347-58. Epub 2007 Feb 1.

31.

The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.

Schmid G, Guba M, Ischenko I, Papyan A, Joka M, Schrepfer S, Bruns CJ, Jauch KW, Heeschen C, Graeb C.

J Cell Biochem. 2007 May 1;101(1):259-70.

PMID:
17203465
32.

FTY720 inhibits tumor growth and angiogenesis.

Schmid G, Guba M, Papyan A, Ischenko I, Brückel M, Bruns CJ, Jauch KW, Graeb C.

Transplant Proc. 2005 Jan-Feb;37(1):110-1.

PMID:
15808563
33.

Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF.

Guba M, Yezhelyev M, Eichhorn ME, Schmid G, Ischenko I, Papyan A, Graeb C, Seeliger H, Geissler EK, Jauch KW, Bruns CJ.

Blood. 2005 Jun 1;105(11):4463-9. Epub 2005 Jan 25.

34.

Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.

Bruell D, Bruns CJ, Yezhelyev M, Huhn M, Müller J, Ischenko I, Fischer R, Finnern R, Jauch KW, Barth S.

Int J Mol Med. 2005 Feb;15(2):305-13.

PMID:
15647848
35.

The C terminus of RON tyrosine kinase plays an autoinhibitory role.

Yokoyama N, Ischenko I, Hayman MJ, Miller WT.

J Biol Chem. 2005 Mar 11;280(10):8893-900. Epub 2005 Jan 4.

36.
37.

Scaffolding protein Gab2 mediates fibroblast transformation by the SEA tyrosine kinase.

Ischenko I, Petrenko O, Gu H, Hayman MJ.

Oncogene. 2003 Sep 25;22(41):6311-8.

PMID:
14508511
39.

Fibroblast growth factor receptor 3 induces gene expression primarily through Ras-independent signal transduction pathways.

Choi DY, Toledo-Aral JJ, Lin HY, Ischenko I, Medina L, Safo P, Mandel G, Levinson SR, Halegoua S, Hayman MJ.

J Biol Chem. 2001 Feb 16;276(7):5116-22. Epub 2000 Nov 17.

40.

Eukaryotic mRNAs encoding abundant and scarce proteins are statistically dissimilar in many structural features.

Kochetov AV, Ischenko IV, Vorobiev DG, Kel AE, Babenko VN, Kisselev LL, Kolchanov NA.

FEBS Lett. 1998 Dec 4;440(3):351-5.

42.
43.

Distinct roles of the receptor tyrosine kinases c-ErbB and c-Kit in regulating the balance between erythroid cell proliferation and differentiation.

Wessely O, Mellitzer G, von Lindern M, Levitzki A, Gazit A, Ischenko I, Hayman MJ, Beug H.

Cell Growth Differ. 1997 May;8(5):481-93.

44.

Phenobarbital-dependent protein binding to Barbie box-like sequences in the coding region of cytochrome P450BM-3 gene from Bacillus megaterium.

Gaidamakova EK, Alpatov OV, Ischenko IV, Kovalenko SP, Lyakhovich VV.

Gene. 1996 Dec 12;183(1-2):97-101.

PMID:
8996092
45.

Transformation of erythroid progenitors by viral and cellular tyrosine kinases.

Beug H, Schroeder C, Wessely O, Deiner E, Meyer S, Ischenko ID, Hayman MJ.

Cell Growth Differ. 1995 Aug;6(8):999-1008.

46.
47.

SITEVIDEO: a computer system for functional site analysis and recognition. Investigation of the human splice sites.

Kel AE, Ponomarenko MP, Likhachev EA, Orlov YuL, Ischenko IV, Milanesi L, Kolchanov NA.

Comput Appl Biosci. 1993 Dec;9(6):617-27.

PMID:
7511478

Supplemental Content

Loading ...
Support Center